PRODUCT INFORMATION

MDMB-4en-PINACA-d_4

Item No. 36754

Formal Name:	3-methyl-N-[[1-(4-penten-1-yl)-1H-indazol-3-yl]carbonyl-d_4]-L-valine, methyl ester
Synonyms:	MDMB-PENINACA-d_4, MDMB-PINACA N1-pentyl-4-en isomer-d_4
MF:	$C_{20}H_{23}D_4N_3O_3$
FW:	361.5
Chemical Purity:	≥98% (MDMB-4en-PINACA)
Deuterium Incorporation:	≥99% deuterated forms (d_1-d_4); ≤1% d_0
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

MDMB-4en-PINACA-d_4 (Item No. 36754) is intended for use as an internal standard for the quantification of MDMB-4en-PINACA (Item Nos. 30761 | 26097) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

MDMB-4en-PINACA is categorized as a synthetic cannabinoid.[1] It substitutes for Δ^9-THC (Item Nos. ISO60157 | 9003771 | 12068) in a drug discrimination test and induces hypothermia in mice.[2] MDMB-4en-PINACA has been associated with overdose and found in samples seized by law enforcement.[3,4] MDMB-4en-PINACA-d4 is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.

Reference

1. Cannaert, A., Sparkes, E., Pike, E., *et al.* Synthesis and *in vitro* cannabinoid receptor 1 activity of recently detected synthetic cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. *ACS Chem. Neurosci.* **11(24),** 4434-4446 (2020).
2. Marusich, J.A., Gamage, T.F., Zhang, Y., *et al.* In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists. *Pharmacol. Biochem. Behav.* **220**, 173467 (2022).
3. Manini, A.F., Krotulski, A.J., Schimmel, J., *et al.* Respiratory failure in confirmed synthetic cannabinoid overdose. *Clin. Toxicol. (Phila)* **60(4)**, 524-526 (2022).
4. Rodrigues, T.B., Souza, M.P., de Melo Barbosa, L., *et al.* Synthetic cannabinoid receptor agonists profile in infused papers seized in Brazilian prisons. *Forensic Toxicol.* **40(1)**, 119-124 (2022).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM